Evidence map›Paper›PMID 26631482›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016

The alternative complement pathway aids in vascular regression during the early stages of a murine model of proliferative retinopathy.

Clifford Kim, Kaylee E Smith, Alexandra Castillejos, Daniel Diaz-Aguilar, Magali Saint-Geniez, Kip M Connor

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Clifford Kim*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA.
Kaylee E Smith*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA.
Alexandra Castillejos*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA.
Daniel Diaz-Aguilar*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA.
Magali Saint-Geniez*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA.
Kip M Connor*Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; and Schepens Eye Research Institute, Boston, Massachusetts, USA kip_connor@meei.harvard.edu.
Harvard University · USMassachusetts Eye and Ear Infirmary · USSmith-Kettlewell Eye Research Institute · US

Funding

P30 Core Grant for Vision ResearchP30EY014104 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Eric A Pierce · 2002 to 2026
$15.1M
Complement Mediated Neovascularization in RetinopathyR01EY022084 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI CONNOR, KIP M · 2012 to 2015
$1.8M
NEI NIH HHS P30 EY014104NEI NIH HHS P30EY014104NEI NIH HHS R01 EY022084NEI NIH HHS R01EY022084/S1
6 · The paper itself

Abstract

Proliferative retinopathic diseases often progress in 2 phases: initial regression of retinal vasculature (phase 1) followed by subsequent neovascularization (NV) (phase 2). The immune system has been shown to aid in vascular pruning in such retinopathies; however, little is known about the role of the alternative complement pathway in the initial vascular regression phase. Using a mouse model of oxygen-induced retinopathy (OIR), we observed that alternative complement pathway-deficient mice (Fb(-/-)) exhibited a mild decrease in vascular loss at postnatal day (P)8 compared with age- and strain-matched controls (P = 0.035). Laser capture microdissection was used to isolate the retinal blood vessels. Expression of the complement inhibitors Cd55 and Cd59 was significantly decreased in blood vessels isolated from hyperoxic retinas compared with those from normoxic control mice. Vegf expression was measured at P8 and found to be significantly lower in OIR mice than in normoxic control mice (P = 0.0048). Further examination of specific Vegf isoform expression revealed a significant decrease in Vegf120 (P = 0.00032) and Vegf188 (P = 0.0092). In conjunction with the major modulating effects of Vegf during early retinal vascular development, our data suggest a modest involvement of the alternative complement pathway in targeting vessels for regression in the initial vaso-obliteration stage of OIR.

Indexed as

AnimalsAnimals, NewbornComplement Pathway, AlternativeDisease Models, AnimalHyperoxiaMiceMice, Inbred C57BLNeovascularization, PathologicOxygenProtein IsoformsRetinaRetinal NeovascularizationRetinal VesselsVascular Endothelial Growth Factor AVitreoretinopathy, ProliferativeOxygenProtein IsoformsVascular Endothelial Growth Factor ACd55Cd59factor binnate immune systemOIRVegf

Identifiers

PMID26631482
PMCPMC4750413
OpenAlexW2269776196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.